Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
84.46
+0.41 (0.49%)
Sep 5, 2025, 11:14 AM - Market open
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$848,213
Profits / Employee
$218,747
Market Cap
210.96B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
AbbVie | 55,000 |
MRK News
- 20 hours ago - Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 1 day ago - Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Business Wire
- 1 day ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 3 days ago - Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector - Business Wire
- 3 days ago - Merck's cholesterol drug meets main goal in late-stage trial - Reuters
- 3 days ago - Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study - Business Wire
- 3 days ago - Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 4 days ago - Top 10 High-Yield Dividend Stocks For September 2025 - Seeking Alpha